Tag: ViGeneron GmbH

August 22, 2023 Off

ViGeneron gets EMA approval for Retinitis Pigmentosa related gene therapy

ViGeneron GmbH, a Germany-based gene therapy company, has received from the European Medicines Agency (EMA) an approval for its Clinical Trial Application (CTA) for VG901, a potentially transformative gene therapy to treat CNGA1-associated Retinitis Pigmentosa (RP), an ocular disorder currently lacking approved therapies.

April 26, 2022 Off

ViGeneron and Daiichi Sankyo to Develop a Novel Gene Therapy for Prevalent Eye Diseases

By Author

ViGeneron GmbH, a next-generation gene therapy company, has announced a follow-on collaboration with Daiichi Sankyo Company, Limited to utilize ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye diseases.